Mavacamten HCM denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy for Mavacamten — and Why You Can Appeal

Mavacamten is a first-in-class cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aetna's step-therapy protocol for mavacamten typically requires documented trial of guideline-directed pharmacologic therapies for oHCM — generally rate-controlling agents such as beta-blockers or non-dihydropyridine calcium channel blockers — before the plan will approve mavacamten. The rationale is that less costly agents should be tried first. However, many patients with oHCM have already tried these agents, are intolerant of them, have contraindications, or have had inadequate symptom control — all of which are grounds for a step-therapy exception or a successful appeal.

## Why Step-Therapy Denials Are Appealable

Step-therapy protocols are administrative constructs, and they can be overridden when the medical record supports it. A patient who has already tried and failed or been unable to tolerate the required step agents has already satisfied the protocol — the appeal just needs to document it clearly. A patient for whom the step agents are clinically inappropriate has grounds for a step-therapy exception. Many states also have statutes requiring insurers to grant exceptions in defined clinical circumstances.

## Federal Appeal Framework

• Step-therapy exception request: File concurrently with or before the formal appeal. Most plans must respond to exception requests, and a well-documented exception can resolve the issue without requiring full external review.
• Internal appeal: Submit within the window in the denial letter. Request Aetna's exact step-therapy criteria for oHCM medications.
• External review (ACA §2719): After exhausting internal appeals, non-grandfathered plan members may request independent external review generally within four months of final denial.
• ERISA §503: Employer-plan members have full-and-fair review rights.
• Expedited review: Available when symptom severity or disease progression creates urgency; 72-hour response required.

## Documentation to Gather

• Prior therapy records: Pharmacy records and chart notes documenting every oHCM medication previously tried — with drug names, dates, durations, and clearly documented outcomes (inadequate response, adverse effects, contraindication).
• Current clinical status: Specialist assessment of current symptom burden, functional class, and echocardiographic findings, demonstrating that the disease is not adequately controlled on available alternatives.
• Prescriber medical-necessity letter: A letter from the treating cardiologist or HCM specialist addressing each step-therapy criterion directly: what was tried, what happened, and why mavacamten is now the appropriate next step per the FDA-approved label and current cardiology society guidelines.
• Applicable guidelines: Reference to current professional society recommendations supporting mavacamten after failure of or intolerance to conventional therapies.

## Criteria-Mapping Structure

Obtain Aetna's step-therapy criteria for oHCM. Build a direct response:

| Step-Therapy Requirement | Chart / Documentation Response | |---|---| | Trial of required first-line agent(s) | [Drug names, dates, duration per pharmacy/chart records] | | Documented failure, intolerance, or contraindication | [Prescriber note with specific clinical reason and date] | | Exception basis (if applicable) | [State law reference or plan exception criteria met] | | Current diagnosis consistent with FDA-approved indication | [ICD code, specialist note confirming symptomatic oHCM] |

A direct, criterion-by-criterion response grounded in the medical record gives the reviewer everything needed to approve the exception or overturn the denial without further information requests.